NEW YORK and SHANGHAI, Aug. 26,
2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc.
(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm
engaged in the drug development of immunotherapies for cancer and
stem cell therapies for degenerative diseases, is scheduled for a
presentation at the 25th Annual Conference of the
Chinese Biopharmaceutical Association-USA (CBA) to be held online August 29-30, 2020.
|
Presentation
Title:
|
"Building a
Competitive Cell Therapy Pipeline for Cancer
Patients"
|
|
Session:
|
Cell and Gene
Therapy
|
|
Speaker:
|
Dr. Yihong Yao, Chief
Scientific Officer, CBMG
|
|
Date:
|
Sunday, August 30,
2020
|
|
Time:
|
10:10 a.m.to 10:35
a.m. EDT
|
|
Location:
|
Broadcast virtually
from Rockville, MD
|
|
Website:
|
https://www.cba-usa.org/content/2020-cba-annual-conference
|
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China
using products from its integrated GMP laboratory. The Company's
GMP facilities in China,
consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory
of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy
Technology Innovation and Application Center" with Thermo Fisher
Scientific. These partnerships focus on improving manufacturing
processes for cell therapies. CBMG currently has ongoing CAR-T
Phase I clinical trials in China.
The China NMPA (formerly CFDA) approved the Company's IND
application for a Phase II trial for AlloJoin®, CBMG's
"Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee
Osteoarthritis (KOA), and has accepted the Company's IND
application for a Phase II trial for ReJoin® autologous haMPC
therapy for the treatment of KOA. The NMPA has also accepted CBMG's
dossier for an IND application for clinical trials of anti-BCMA
CAR-T. CBMG is included in the broad-market Russell 3000® Index the
small-cap Russell 2000® Index and the Loncar China BioPharma index.
To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Company Contact:
Derrick C.
Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-present-at-chinese-biopharmaceutical-association-usa-annual-conference-301118884.html
SOURCE Cellular Biomedicine Group